BIO, Two Drugmakers Side with Amgen in Biosimilar Case

Generic Line
An industry group and two drugmakers have filed briefs in the Supreme Court backing Amgen’s request that a federal circuit ruling be partially affirmed to mandate that biosimilar makers share information and wait six months after an FDA approval to launch a therapy.

To View This Article:


Subscribe To Generic Line